Topical Infliximab for Sterile Corneal Melt
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02987686|
Recruitment Status : Recruiting
First Posted : December 9, 2016
Last Update Posted : July 24, 2018
Corneal melt is a complication that could affect very ill eyes and lead to the thinning of the cornea (the clear window covering of the eyes). This thinning can lead to severe consequences such as the leakage of the liquid inside the eye (ocular perforation), or even blindness. Corneal melt can be caused by certain infections or as a sterile process. This project only includes patients with a sterile corneal melt (without an infection) caused by diseases such as rosacea, Sjogren's syndrome, rheumatoid arthritis, Crohn's disease, Stevens Johnson syndrome, as well as toxic epidermal necrolysis or mucous membrane pemphigoid.
Infliximab is an antibody against tumour necrosis factor alpha and has been used to treat or prevent corneal melt in certain patients with inflammatory of auto-immune disease. In this situation, infliximab was used intravenous (using veins) in order to treat the whole body.
This study's hypothesis is that infliximab can safely be used as eye drops for the treatment of sterile corneal melt.
|Condition or disease||Intervention/treatment||Phase|
|Sterile Corneal Melt||Drug: Topical Infliximab||Phase 1|
This is an unmasked, prospective, single-center trial of twelve patients with sterile corneal melt and an underlying auto-immune or inflammatory disease, such as rosacea, Sjogren's syndrome, rheumatoid arthritis, Crohn's disease, Stevens Johnson syndrome, as well as toxic epidermal necrolysis or mucous membrane pemphigoid.
The aim of this phase I study is to evaluate the safety and tolerability of topical infliximab 10mg/ml eye drops for the treatment of corneal melt. As such, six (6) subjects will be recruited in the experimental treatment study and six (6) subjects will be enrolled in the parallel observational study. Indeed, candidates having all inclusion criteria but one exclusion criteria (which are contraindication to infliximab use), will be recruited in the observational study, will receive the standard treatment without infliximab.
During the treatment period, subjects in the therapeutic study will receive topical infliximab 10mg/ml four (4) times per day for four (4) weeks. In order to determine the safety profile, potential side effects as well as the course of the disease, subjects will be monitored while on the study medication as well as for 8 weeks following discontinuation of the drug. The ophthalmological follow-up will be identical in the two groups. However, only subjects enrolled in the experimental treatment study will receive additional laboratory tests. The total study duration for each patient will be 12 weeks.
In terms of statistical analysis, the investigators will focus on describing the outcome measured in the study. For instance, the investigators will describe the number and proportion of side effects, the number of patients with a quiescent corneal melt at 4 weeks and the patients who required a tectonic surgery at 12 weeks post-treatment. The investigators will report the average and standard of deviation of the OSDI score, the epithelial deficit surface as well as the minimal corneal thickness. Moreover, the investigators will perform exploratory statistical analysis in order to study the disease course of each subject and comparing the addition of infliximab to the standard.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||12 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Topical Infliximab for the Treatment of Sterile Corneal Melt|
|Actual Study Start Date :||April 1, 2017|
|Estimated Primary Completion Date :||July 1, 2020|
|Estimated Study Completion Date :||July 1, 2020|
Experimental: Topical Infliximab
Additionally to standard treatment, patients with all inclusive criteria and none exclusive criteria will be included in the therapeutic group and will receive topical infliximab QID for 4 weeks.
Drug: Topical Infliximab
Aside from the standard treatment, patients will receive topical infliximab ( 10mg/ml) four (4) time per day for four (4) weeks.
Other Name: Remicade
No Intervention: Observational group
Patients with all inclusive criteria and one exclusive criteria will receive the standard treatment, without topical infliximab.
- Adverse Events [ Time Frame: 12 weeks ]Number and type of adverse events
- Percentage of patients finishing 4 weeks of infliximab use [ Time Frame: 4 weeks ]Percentage of patients finishing 4 weeks of infliximab use
- Visual Acuity [ Time Frame: 4 and 12 weeks ]Visual Acuity is measured using a Snellen chart
- Ocular surface symptoms as assessed by ocular disease index score [ Time Frame: 4 and 12 weeks ]Ocular surface symptoms as assessed by ocular disease index score
- Conjunctival hyperemia using a slit-lamp photographs [ Time Frame: 4 and 12 weeks ]Conjunctival hyperemia using a slit-lamp photographs
- Corneal thickness as measured by anterior segment optical coherence tomography [ Time Frame: 4 weeks ]Corneal thickness as measured by anterior segment optical coherence tomography
- Surface area of the corneal melt using a slit-lamp photographs [ Time Frame: 4 weeks ]Surface area of the corneal melt using a slit-lamp photographs
- Quiescent corneal state [ Time Frame: 4 weeks ]Percentage of eyes presenting a quiescent corneal state at 4 weeks
- Eyes requiring tectonic surgery [ Time Frame: 12 weeks ]Percentage of eyes requiring tectonic surgery at 12 weeks
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02987686
|Contact: Marie-Claude Robert, MD||514 890-8000 ext email@example.com|
|Contact: Marie-Catherine Tessier||514 890-8000 ext firstname.lastname@example.org|
|Centre Hospitalier de l'Université de Montréal||Recruiting|
|Montreal, Quebec, Canada, H2X3E4|
|Contact: Marie-Catherine Tessier 5148908000 ext 11550|
|Principal Investigator:||Marie-Claude Robert, MD||Centre hospitalier de l'Université de Montréal (CHUM)|